Literature DB >> 15728924

In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively.

D Gruson1, S Pereyre, H Renaudin, A Charron, C Bébéar, C M Bébéar.   

Abstract

Selection of resistant mutants in sequential subcultures with increasing concentrations of six and four different fluoroquinolones was studied for one reference strain each of Mycoplasma pneumoniae and Mycoplasma hominis, respectively. All fluoroquinolones tested selected for resistance, with alterations affecting the quinolone resistance-determining regions of the four target topoisomerase genes.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15728924      PMCID： PMC549269          DOI： 10.1128/AAC.49.3.1190-1193.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Analysis of the gyrA and parC genes of Mycoplasma genitalium detected in first-pass urine of men with non-gonococcal urethritis before and after fluoroquinolone treatment.

Authors:  T Deguchi; S Maeda; M Tamaki; T Yoshida; H Ishiko; M Ito; S Yokoi; Y Takahashi; S Ishihara
Journal:  J Antimicrob Chemother       Date:  2001-11       Impact factor: 5.790

2.  Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.

Authors:  K Nagai; T A Davies; B E Dewasse; M R Jacobs; P C Appelbaum
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

3.  DNA gyrase and topoisomerase IV mutations in clinical isolates of Ureaplasma spp. and Mycoplasma hominis resistant to fluoroquinolones.

Authors:  C M Bébéar; H Renaudin; A Charron; M Clerc; S Pereyre; C Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

4.  Complete sequence analysis of the genome of the bacterium Mycoplasma pneumoniae.

Authors:  R Himmelreich; H Hilbert; H Plagens; E Pirkl; B C Li; R Herrmann
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

5.  Sparfloxacin selects gyrase mutations in first-step Mycoplasma hominis mutants, whereas ofloxacin selects topoisomerase IV mutations.

Authors:  G E Kenny; P A Young; F D Cartwright; K E Sjöström; W M Huang
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

6.  Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro.

Authors:  C M Bébéar; H Renaudin; A Charron; J M Bové; C Bébéar; J Renaudin
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

7.  Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

Authors:  C M Bebear; J Renaudin; A Charron; H Renaudin; B de Barbeyrac; T Schaeverbeke; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis.

Authors:  S Raherison; P Gonzalez; H Renaudin; A Charron; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

9.  DNA gyrase and topoisomerase IV mutations associated with fluoroquinolone resistance in Proteus mirabilis.

Authors:  L M Weigel; G J Anderson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae.

Authors:  S Pereyre; C Guyot; H Renaudin; A Charron; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191
  10 in total
  23 in total

1.  Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.

Authors:  Tsutomu Yamazaki; Tsuguo Sasaki; Masahiro Takahata
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

2.  Fluoroquinolone and macrolide resistance-associated mutations in Mycoplasma genitalium.

Authors:  Kaitlin A Tagg; Neisha J Jeoffreys; Deborah L Couldwell; Jennifer A Donald; Gwendolyn L Gilbert
Journal:  J Clin Microbiol       Date:  2013-05-08       Impact factor: 5.948

3.  Mutations Associated with Decreased Susceptibility to Seven Antimicrobial Families in Field and Laboratory-Derived Mycoplasma bovis Strains.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Enikő Wehmann; Inna Lysnyansky; Krisztián Bányai; Szilvia Marton; Ákos Jerzsele; Zsuzsanna Rónai; Ibolya Turcsányi; László Makrai; Szilárd Jánosi; Sára Ágnes Nagy; Miklós Gyuranecz
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

Review 4.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

5.  Development of a Multilocus Sequence Typing Scheme for Molecular Typing of Mycoplasma pneumoniae.

Authors:  Rebecca J Brown; Matthew T G Holden; O Brad Spiller; Victoria J Chalker
Journal:  J Clin Microbiol       Date:  2015-07-22       Impact factor: 5.948

6.  Levels of Mycoplasma genitalium Antimicrobial Resistance Differ by Both Region and Gender in the State of Queensland, Australia: Implications for Treatment Guidelines.

Authors:  E L Sweeney; E Trembizki; C Bletchly; C S Bradshaw; A Menon; F Francis; J Langton-Lockton; G R Nimmo; D M Whiley
Journal:  J Clin Microbiol       Date:  2019-02-27       Impact factor: 5.948

Review 7.  New insights into the pathogenesis and detection of Mycoplasma pneumoniae infections.

Authors:  Ken B Waites; Mitchell F Balish; T Prescott Atkinson
Journal:  Future Microbiol       Date:  2008-12       Impact factor: 3.165

8.  Contribution of topoisomerase IV mutation to quinolone resistance in Mycoplasma genitalium.

Authors:  Yuko Yamaguchi; Masaya Takei; Ryuta Kishii; Mitsuru Yasuda; Takashi Deguchi
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

9.  Alterations in the Quinolone Resistance-Determining Regions and Fluoroquinolone Resistance in Clinical Isolates and Laboratory-Derived Mutants of Mycoplasma bovis: Not All Genotypes May Be Equal.

Authors:  Dima Khalil; Claire A M Becker; Florence Tardy
Journal:  Appl Environ Microbiol       Date:  2015-12-04       Impact factor: 4.792

10.  The role of Mycoplasma in upper respiratory infections.

Authors:  Ken B Waites; T Prescott Atkinson
Journal:  Curr Infect Dis Rep       Date:  2009-05       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.